Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma November 24, 2025
Positive Results Reported from Bezuclastinib PEAK Ph 3 Trial in Gastrointestinal Stromal Tumors (GIST) November 18, 2025
77.8% Three-Month Complete Response Rate Reported from Ph 3 UTOPIA Trial of UGN-103; FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Received November 10, 2025
FAILED TRIAL: Ph 3 ASCENT-07 study of Trodelvy® (sacituzumab govitecan-hziy) vs chemo in 1L HR+/HER2-neg metastatic breast cancer patients did not meet the primary endpoint of PFS November 10, 2025
Positive Data from ANTLER Ph 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010) Announced November 10, 2025
Positive Findings from Longer-Term Analysis of Ph 3 INDIGO Trial Showing Continued Durable Benefit of VORANIGO® (vorasidenib) Published in The Lancet Oncology November 10, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
KEYTRUDA + WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell RCC Following Nephrectomy November 4, 2025
FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced November 4, 2025
WELIREG + LENVIMA Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC November 4, 2025
Updated Rezatapopt Monotherapy Interim Data Announced From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation October 29, 2025
Updated Elironrasib Safety & Efficacy Data in Patients with KRAS G12C NSCLC Following Treatment with a KRAS(OFF) G12C Inhibitor Presented October 29, 2025
Preliminary Data from Ongoing Ph 1/2a Dose Escalation Trial of VS-7375 in Patients with KRAS G12D Mutant Solid Tumors Announced October 29, 2025
NANETS 2025: Ph 3 COMPETE Data Shows Higher ORRs with ITM-11 vs. Everolimus Across Subgroups of Patients with GEP-NETs presented October 29, 2025
Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002 October 29, 2025
Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced October 29, 2025
PROs from VERITAC-2 Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy October 29, 2025
Positive Data from Ongoing Ph 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers Reported October 29, 2025
